MEGHANA TRIVEDI to Receptors, Estrogen
This is a "connection" page, showing publications MEGHANA TRIVEDI has written about Receptors, Estrogen.
Connection Strength
0.773
-
Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast. 2011 Oct; 20 Suppl 3:S42-9.
Score: 0.238
-
Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution. Clin Breast Cancer. 2020 12; 20(6):520-526.
Score: 0.109
-
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339.
Score: 0.098
-
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81.
Score: 0.081
-
The changing role of ER in endocrine resistance. Breast. 2015 Nov; 24 Suppl 2:S60-6.
Score: 0.078
-
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015 Sep 01; 21(17):3995-4003.
Score: 0.077
-
Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 2013 Dec 01; 19(23):6389-97.
Score: 0.069
-
Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients. Ann Pharmacother. 2019 05; 53(5):501-509.
Score: 0.024